184 related articles for article (PubMed ID: 26446051)
1. ABO blood group incompatibility as an adverse risk factor for outcomes in patients with myelodysplastic syndromes and acute myeloid leukemia undergoing HLA-matched peripheral blood hematopoietic cell transplantation after reduced-intensity conditioning.
Hefazi M; Litzow M; Hogan W; Gastineau D; Jacob E; Damlaj M; Hashmi S; Al-Kali A; Patnaik MM
Transfusion; 2016 Feb; 56(2):518-27. PubMed ID: 26446051
[TBL] [Abstract][Full Text] [Related]
2. Prolonged isolated red blood cell transfusion requirement after allogeneic blood stem cell transplantation: identification of patients at risk.
Dahl D; Hahn A; Koenecke C; Heuft HG; Dammann E; Stadler M; Buchholz S; Krauter J; Eder M; Sykora KW; Klein C; Ganser A; Sauer M
Transfusion; 2010 Mar; 50(3):649-55. PubMed ID: 19929861
[TBL] [Abstract][Full Text] [Related]
3. Impact of ABO incompatibility on allogeneic peripheral blood progenitor cell transplantation after reduced intensity conditioning.
Canals C; Muñiz-Díaz E; Martínez C; Martino R; Moreno I; Ramos A; Arilla M; Boto N; Pastoret C; Remacha A; Sierra J; Madoz P
Transfusion; 2004 Nov; 44(11):1603-11. PubMed ID: 15504166
[TBL] [Abstract][Full Text] [Related]
4. Sustained remissions of high-risk acute myeloid leukemia and myelodysplastic syndrome after reduced-intensity conditioning allogeneic hematopoietic transplantation: chronic graft-versus-host disease is the strongest factor improving survival.
Valcárcel D; Martino R; Caballero D; Martin J; Ferra C; Nieto JB; Sampol A; Bernal MT; Piñana JL; Vazquez L; Ribera JM; Besalduch J; Moraleda JM; Carrera D; Brunet MS; Perez-Simón JA; Sierra J
J Clin Oncol; 2008 Feb; 26(4):577-84. PubMed ID: 18086801
[TBL] [Abstract][Full Text] [Related]
5. Prophylactic red blood cell exchange for prevention of severe immune hemolysis in minor ABO-mismatched allogeneic peripheral blood progenitor cell transplantation after reduced-intensity conditioning.
Worel N; Greinix HT; Supper V; Leitner G; Mitterbauer M; Rabitsch W; Fischer G; Rosenmayr A; Höcker P; Kalhs P
Transfusion; 2007 Aug; 47(8):1494-502. PubMed ID: 17655594
[TBL] [Abstract][Full Text] [Related]
6. Consequences of ABO incompatibility in multiple myeloma patients undergoing peripheral blood stem cell transplantation after reduced intensity conditioning.
Marenchino D; Maddalena L; Balbo R; Avonto I; Menardi G; Prucca M; Perotti L; Mordini N; Peano G
Blood Transfus; 2011 Jan; 9(1):79-85. PubMed ID: 21084015
[TBL] [Abstract][Full Text] [Related]
7. Allogeneic stem cell transplantation after a fludarabine/busulfan-based reduced-intensity conditioning in patients with myelodysplastic syndrome or secondary acute myeloid leukemia.
Kröger N; Bornhäuser M; Ehninger G; Schwerdtfeger R; Biersack H; Sayer HG; Wandt H; Schäfer-Eckardt K; Beyer J; Kiehl M; Zander AR;
Ann Hematol; 2003 Jun; 82(6):336-42. PubMed ID: 12728337
[TBL] [Abstract][Full Text] [Related]
8. ABO incompatibility is associated with increased non-relapse and GVHD related mortality in patients with malignancies treated with a reduced intensity regimen: a single center experience of 221 patients.
Resnick IB; Tsirigotis PD; Shapira MY; Aker M; Bitan M; Samuel S; Abdul-Hai A; Ackerstein A; Or R; Slavin S
Biol Blood Marrow Transplant; 2008 Apr; 14(4):409-17. PubMed ID: 18342783
[TBL] [Abstract][Full Text] [Related]
9. Safety and impact of donor-type red blood cell transfusion before allogeneic peripheral blood progenitor cell transplantation with major ABO mismatch.
Scholl S; Klink A; Mügge LO; Schilling K; Höffken K; Sayer HG
Transfusion; 2005 Oct; 45(10):1676-83. PubMed ID: 16181220
[TBL] [Abstract][Full Text] [Related]
10. Impact of ABO-incompatible donor on early and late outcome of hematopoietic stem cell transplantation.
Ozkurt ZN; Yegin ZA; Yenicesu I; Aki SZ; Yagci M; Sucak GT
Transplant Proc; 2009 Nov; 41(9):3851-8. PubMed ID: 19917400
[TBL] [Abstract][Full Text] [Related]
11. Effect of age on outcome of reduced-intensity hematopoietic cell transplantation for older patients with acute myeloid leukemia in first complete remission or with myelodysplastic syndrome.
McClune BL; Weisdorf DJ; Pedersen TL; Tunes da Silva G; Tallman MS; Sierra J; Dipersio J; Keating A; Gale RP; George B; Gupta V; Hahn T; Isola L; Jagasia M; Lazarus H; Marks D; Maziarz R; Waller EK; Bredeson C; Giralt S
J Clin Oncol; 2010 Apr; 28(11):1878-87. PubMed ID: 20212255
[TBL] [Abstract][Full Text] [Related]
12. Impact of ABO incompatibility on outcome after allogeneic peripheral blood stem cell transplantation.
Kim JG; Sohn SK; Kim DH; Baek JH; Lee KB; Min WS; Kim CC; Lee MH; Lee JJ; Chung IJ; Kim HJ; Lee JW
Bone Marrow Transplant; 2005 Mar; 35(5):489-95. PubMed ID: 15654350
[TBL] [Abstract][Full Text] [Related]
13. Hematopoietic stem cell transplantation after reduced intensity conditioning in acute myelogenous leukemia patients older than 40 years.
Huisman C; Meijer E; Petersen EJ; Lokhorst HM; Verdonck LF
Biol Blood Marrow Transplant; 2008 Feb; 14(2):181-6. PubMed ID: 18215778
[TBL] [Abstract][Full Text] [Related]
14. Outcomes after major or bidirectional ABO-mismatched allogeneic hematopoietic progenitor cell transplantation after pretransplant isoagglutinin reduction with donor-type secretor plasma with or without plasma exchange.
Curley C; Pillai E; Mudie K; Western R; Hutchins C; Durrant S; Kennedy GA
Transfusion; 2012 Feb; 52(2):291-7. PubMed ID: 21848968
[TBL] [Abstract][Full Text] [Related]
15. Impact of donor-recipient major ABO mismatch on allogeneic transplantation outcome according to stem cell source.
Blin N; Traineau R; Houssin S; Peffault de Latour R; Petropoulou A; Robin M; Larghero J; Ribaud P; Socié G
Biol Blood Marrow Transplant; 2010 Sep; 16(9):1315-23. PubMed ID: 20353831
[TBL] [Abstract][Full Text] [Related]
16. Allogeneic stem cell transplantation for adults with myelodysplastic syndromes: importance of pretransplant disease burden.
Warlick ED; Cioc A; Defor T; Dolan M; Weisdorf D
Biol Blood Marrow Transplant; 2009 Jan; 15(1):30-8. PubMed ID: 19135940
[TBL] [Abstract][Full Text] [Related]
17. ABO blood group barrier in allogeneic bone marrow transplantation revisited.
Seebach JD; Stussi G; Passweg JR; Loberiza FR; Gajewski JL; Keating A; Goerner M; Rowlings PA; Tiberghien P; Elfenbein GJ; Gale RP; van Rood JJ; Reddy V; Gluckman E; Bolwell BJ; Klumpp TR; Horowitz MM; Ringdén O; Barrett AJ;
Biol Blood Marrow Transplant; 2005 Dec; 11(12):1006-13. PubMed ID: 16338623
[TBL] [Abstract][Full Text] [Related]
18. ABO mismatch may affect engraftment in multiple myeloma patients receiving nonmyeloablative conditioning.
Badros A; Tricot G; Toor A; Morris C; Guo C; Munshi N; Barlogie B; Cottler-Fox M
Transfusion; 2002 Feb; 42(2):205-9. PubMed ID: 11896336
[TBL] [Abstract][Full Text] [Related]
19. Consequences of ABO incompatibility in allogeneic hematopoietic stem cell transplantation.
Stussi G; Muntwyler J; Passweg JR; Seebach L; Schanz U; Gmür J; Gratwohl A; Seebach JD
Bone Marrow Transplant; 2002 Jul; 30(2):87-93. PubMed ID: 12132047
[TBL] [Abstract][Full Text] [Related]
20. Role of HCT-comorbidity index, age and disease status at transplantation in predicting survival and non-relapse mortality in patients with myelodysplasia and leukemia undergoing reduced-intensity-conditioning hemopoeitic progenitor cell transplantation.
Bokhari SW; Watson L; Nagra S; Cook M; Byrne JL; Craddock C; Russell NH
Bone Marrow Transplant; 2012 Apr; 47(4):528-34. PubMed ID: 21743502
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
